| 30th Apr 2024 1:00 pm |
RNS |
Board Change |
| 16th Apr 2024 7:00 am |
RNS |
Faron confirms plans under new leadership |
| 15th Apr 2024 7:00 am |
RNS |
Appointment of Chief Financial Officer |
| 8th Apr 2024 7:10 am |
RNS |
Approval of Warrant Terms and Conditions |
| 8th Apr 2024 7:05 am |
RNS |
Decisions of the Board of Directors |
| 8th Apr 2024 7:00 am |
RNS |
Appointment of Chief Executive Officer |
| 5th Apr 2024 12:00 pm |
RNS |
Results of the Annual General Meeting |
| 4th Apr 2024 7:00 am |
RNS |
Announcement of Placing |
| 28th Mar 2024 7:00 am |
RNS |
Issue of Warrants to IPF Funding Update |
| 26th Mar 2024 10:00 am |
RNS |
Faron´s Annual Report 2023 |
| 18th Mar 2024 7:00 am |
RNS |
Additional Positive Data from Phase 1 of BEXMAB |
| 14th Mar 2024 7:00 am |
RNS |
Faron to Host BEXMAB Webcast |
| 13th Mar 2024 2:00 pm |
RNS |
Notice of Annual General Meeting 2024 |
| 13th Mar 2024 7:00 am |
RNS |
Financial Statement January 1 to December 31 2023 |
| 4th Mar 2024 7:00 am |
RNS |
Binding commitments for convertible loans |
| 28th Feb 2024 4:00 pm |
RNS |
Replacement - Update to 2024 Financial Calendar |
| 27th Feb 2024 6:00 pm |
RNS |
Update to Faron’s Financial Calendar for 2024 |
| 21st Feb 2024 2:00 pm |
RNS |
Continued Negotiations Regarding Events of Default |
| 19th Feb 2024 10:30 am |
RNS |
Events of Default |
| 31st Jan 2024 7:00 am |
RNS |
Further re: Exercise of options |
| 25th Jan 2024 7:00 am |
RNS |
BEXMAB Insights into Patient Profiles |
| 19th Jan 2024 1:00 pm |
RNS |
Exercise of options - Issue of equity |
| 9th Jan 2024 7:00 am |
RNS |
First Patient Dosed in Ph 2 of the BEXMAB Trial |
| 3rd Jan 2024 7:00 am |
RNS |
Presentation at J.P. Morgan Healthcare Conference |
| 22nd Dec 2023 7:00 am |
RNS |
Faron’s Financial Calendar for 2024 |
| 11th Dec 2023 7:00 am |
RNS |
Phase 1 BEXMAB data presented at ASH |
| 7th Dec 2023 7:00 am |
RNS |
MATINS Trial in Cell Reports Medicine |
| 4th Dec 2023 7:00 am |
RNS |
Grant of options |
| 6th Nov 2023 8:13 am |
RNS |
Faron Initiates Phase 2 Part of BEXMAB Study |
| 6th Nov 2023 7:00 am |
RNS |
Faron Initiates Phase 2 Part of BEXMAB Study |
| 2nd Nov 2023 1:00 pm |
RNS |
Faron to present data from BEXMAB study at ASH |
| 27th Oct 2023 1:00 pm |
RNS |
Manager's transactions |
| 27th Oct 2023 7:15 am |
RNS |
Exercise of options |
| 27th Oct 2023 7:00 am |
RNS |
Results of Placing |
| 26th Oct 2023 4:30 pm |
RNS |
Proposed Issue and Placing |
| 11th Oct 2023 7:00 am |
RNS |
Faron Announces Positive BEXMAB Study Update |
| 3rd Oct 2023 7:00 am |
RNS |
Faron to host webcast on new BEXMAB study data |
| 22nd Sep 2023 4:00 pm |
RNS |
Board Changes |
| 22nd Sep 2023 11:00 am |
RNS |
Results of EGM |
| 21st Sep 2023 7:00 am |
RNS |
Faron Appoints Interim Chief Medical Officer |
